Citius Oncology Launches Lymphir In US For Skin Cancer
Synopsis
The drug is an IL-2 receptor-directed fusion protein designed to kill IL-2R–expressing cancer cells while depleting regulatory T cells.
Citius Oncology (CTOR) said on Monday it has launched Lymphir, a newly approved cancer immunotherapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL), making the drug available nationwide through specialty distributors.
The U.S. Food and Drug Administration (FDA) approved Lymphir, also known as denileukin diftitox-cxdlfor adults with cutaneous T-cell lymphoma, a form of skin cancer that can cause painful, itchy lesions. The drug is an IL-2 receptor-directed fusion protein designed to kill IL-2R–expressing cancer cells while depleting regulatory T cells.
The stock jumped nearly 14% at the time of writing.
Get updates to this developing story directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.